SCHEMBL3697006

SCHEMBL3697006

O=C(c1ccccc1)c1c(Cl)ccc2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.48
ALDH1A1 P00352 2/20 0.46
CYP1A2 P05177 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
CYP2C19 P33261 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GLA P06280 1/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
VCAM1 P19320 1/20 0.45
ABCG2 Q9UNQ0 2/20 0.43
CNR2 P34972 1/20 0.43
WDR5 P61964 1/20 0.43
HTT P42858 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3786628 0.91 HPRT1 (0.47) CYP2A6ALDH1A1HPGDHSD17B10NPC1
SCHEMBL3703634 0.91 HPRT1 (0.47) CYP2A6ALDH1A1HPGDHSD17B10NPC1
SCHEMBL3146455 0.85 HSD17B10 (0.59) CYP2A6ALDH1A1CYP1A2MEN1KMT2A
SCHEMBL3699078 0.84 MEN1 (0.46) ALDH1A1CYP1A2MEN1KMT2ACYP2C19
Hydrochloric Acid SCHEMBL11726958 0.83 KMT2A (0.57) CYP2A6ALDH1A1CYP1A2MEN1KMT2A
SCHEMBL3706346 0.83 MEN1 (0.44) ALDH1A1CYP1A2MEN1KMT2ACYP2C19
SCHEMBL3778102 0.83 MEN1 (0.44) ALDH1A1CYP1A2MEN1KMT2ACYP2C19
SCHEMBL6609007 0.81 ALDH1A1 (0.54) CYP2A6ALDH1A1CYP1A2MEN1KMT2A
SCHEMBL31304979 0.79 WDR5 (0.53) ALDH1A1CYP1A2MEN1KMT2ACYP2C19
SCHEMBL5817920 0.79 ABCG2 (0.57) ALDH1A1CYP1A2MEN1KMT2ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2460789-B1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL CO (JP) 2017-04-19 EP disclosed
US-9079830-B2 Method for producing biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-07-14 US disclosed
EP-2460789-A1 METHOD FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2012-06-06 EP disclosed
US-20120123154-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-17 US disclosed
EP-0039795-B1 PROCESS FOR THE PREPARATION OF 1,2-BENZISOTHIAZOLES BASF Aktiengesellschaft (DE) 1983-10-12 EP disclosed
EP-0039795-A1 Process for the preparation of 1,2-benzisothiazoles BASF Aktiengesellschaft (DE) 1981-11-18 EP disclosed
US-4277477-A TREATING CARDIAC ARRHYTHMIA BASF AKTIENGESELLSCHAFT (DE) 1981-07-07 US disclosed
EP-0000750-A1 1,2-Benzisothiazoles and process for their preparation BASF Aktiengesellschaft (DE) 1979-02-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120123154-A1 METHOD FOR PRODUCING BIARYL COMPOUND AKR7A2, AOC2, CBR1 CYP2A6 47/4885ALDH1A1 35/4885CYP1A2 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.